The full run of the weekly brief on psychedelic medicine, newest first.
A compound with no perceptual effect just became a nine-figure bet. Read into that.
By Jama Pitman62 brains, four settings, one drug. The pattern only shows up in the imaging.
By Bryan SmithTwo mega-deals in eleven months, and what they actually tell us about where this field stands.
By Domenic SuppaNew pilot data begins to fill the exact efficacy gap this newsletter flagged three weeks ago.
By Rotem PetrankerOregon's program has served 16,000 people. The VA trial enrolled its first veteran weeks ago.
By Burton TabaacNew 2026 research shows exactly which brain circuits a single psilocybin dose rewires, and for how long.
By Bryan SmithA dedicated PTSD safety trial, and 12-month veteran data on how long the effect actually lasts.
By Rotem PetrankerTwo consecutive Phase 3 successes, a Zurich hospital study, and what Spravato's path tells us about where coverage likely goes next.
By Jama PitmanThe fastest federal move in this space in decades. Here is what it actually changes.
By Jama PitmanThe neuroplasticity window, decoded, and data from 80 veterans that shows what it looks like in practice.
By Domenic Suppa